SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bong who wrote (30)6/11/2001 8:42:06 PM
From: tom pope  Read Replies (1) of 78
 
This is several hours old, but since nobody else has posted this, I thought I might - from Briefing:

>>15:57 ET PRAECIS (PRCS) 22.26 -3.15: Sources at CIBC World Markets telling Briefing.com that the firm says stock is weak on speculation by another brokerage firm that PRCS has received an FDA warning letter indicating that additional data points on Abarelix (prostate cancer drug) are needed, but CIBC spoke with top management and was told that the company has not received any warning letter<<

I bought some AH and am now underwater if the bid is to be taken seriously. When the blurb says >>top management<< I hope they don't mean IR. They're always the last to know.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News